Top

Journal of Hepato-Biliary-Pancreatic Sciences

Published in:

01-03-2011 | Original article

Protease-activated receptor-2 regulates cyclooxygenase-2 expression in human bile duct cancer via the pathways of mitogen-activated protein kinases and nuclear factor kappa B

Authors: Hidetoshi Eguchi, Kentaro Iwaki, Kohei Shibata, Tadashi Ogawa, Masayuki Ohta, Seigo Kitano

Published in: Journal of Hepato-Biliary-Pancreatic Sciences | Issue 2/2011

Abstract

Background/purpose

Recent studies have suggested that protease-activated receptor-2 (PAR-2) activity correlates with cell proliferation and tumor growth, and its activation induces expression of cyclooxygenase-2 (COX-2). However, no previous reports have investigated PAR-2 signaling pathways in bile duct cancer. The aim of this study was to determine whether PAR-2 activation can regulate COX-2 expression via mitogen-activated protein kinases (MAPKs) and nuclear factor kappa B (NF-κB) in human bile duct cancer cells.

Methods

We immunohistochemically examined PAR-2 and COX-2 expression in 104 resected human specimens of extrahepatic bile duct cancer. We then determined how inhibitors of MAPKs and NF-κB signaling pathways influence COX-2 expression under PAR-2 activation in HuCCT1 and TKKK, human bile duct cancer cell lines.

Results

PAR-2 and COX-2 proteins were immunohistochemically recognized in 63 and 57% of specimens and were significantly correlated. PAR-2 agonist peptide activated mRNA and protein expression of COX-2 in HuCCT1 and TKKK. Pharmacologic blockade of p44/42 or p38 MAPK significantly inhibited PAR-2-activated mRNA and protein expression of COX-2 in both cells. COX-2 protein expression was also inhibited by the blocker of NF-κB pathway in both cells.

Conclusions

PAR-2 may regulate COX-2 expression in human bile duct cancer via the MAPKs and NF-κB pathways.

Ishak KG, Anthony PP, Sobin LH. Histological typing of tumours of the liver. WHO international histological classification of tumours. Berlin: Springer; 1994.

Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004;24:115–25.PubMedCrossRef

Babbitt DP. Congenital choledochal cyst: new etiological concept based on anomalous relationships of the common bile duct and pancreatic bulb. Ann Radiol (Paris). 1969;12:231–40.

Tsuchiya R, Harada N, Ito T, Furukawa M, Yoshihiro I. Malignant tumors in choledochal cyst. Ann Surg. 1977;186:22–8.PubMedCrossRef

Kinoshita H, Nagata E, Hirohashi K, Sakai K, Kobayashi Y. Carcinoma of the gallbladder with an anomalous connection between the choledochus and the pancreatic duct. Cancer. 1984;54:762–9.PubMedCrossRef

Mori K, Nagakawa T, Ohta T, Nakano T, Kayahara M, Kanno M, et al. Association between gallbladder cancer and anomalous union of the pancreaticobiliary duct system. Hepatogastroenterology. 1993;40:56–60.PubMed

Sandoh N, Shirai Y, Hatakeyama K. Incidence of anomalous union of the pancreaticobiliary ductal system in biliary cancer. Hepatogastroenterology. 1997;44:1580–3.PubMed

Chao TC, Jan YY, Chen MF. Primary carcinoma of the gallbladder associated with anomalous pancreaticobiliary ductal junction. J Clin Gastroenterol. 1995;21:306–8.PubMedCrossRef

Yamauchi S, Koga A, Matsumoto S, Tanaka M, Nakayama F. Anomalous junction of pancreaticobiliary duct without congenital choledochal cyst: a possible risk factor for gallbladder carcinoma. Am J Gastroenterol. 1987;82:20–4.PubMed

10.

Nagata E, Sakai K, Kinoshita H, Kobayashi Y. The relation between carcinoma of the gallbladder and an anomalous connection between the choledochus and the pancreatic duct. Ann Surg. 1985;202:182–90.PubMedCrossRef

11.

Hollenberg MD. Protease-mediated signaling: new paradigms for cell regulation and drug development. Trends Pharmacol Sci. 1996;17:3–6.PubMedCrossRef

12.

Steinhoff M, Buddenkotte J, Shpacovitch V, Rattenholl A, Moormann C, Vergnolle N, et al. Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. Endocr Rev. 2005;26:1–43.PubMedCrossRef

13.

Ramachandran R, Hollenberg MD. Proteinases and signaling: pathophysiological and therapeutic implications via PARs and more. Br J Pharmacol. 2008;153(Suppl 1):S263–82.PubMed

14.

Brass LF, Molino M. Protease-activated G protein-coupled receptors on human platelets and endothelial cells. Thromb Haemost. 1997;78:234–41.PubMed

15.

Bohm SK, Kong W, Bromme D, Smeekens SP, Anderson DC, Connolly A, et al. Molecular cloning, expression and potential functions of the human proteinase-activated receptor-2. Biochem J. 1996;314(Part 3):1009–16.PubMed

16.

Nystedt S, Emilsson K, Larsson AK, Strombeck B, Sundelin J. Molecular cloning and functional expression of the gene encoding the human proteinase-activated receptor 2. Eur J Biochem. 1995;232:84–9.PubMedCrossRef

17.

D’Andrea MR, Derian CK, Leturcq D, Baker SM, Brunmark A, Ling P, et al. Characterization of protease-activated receptor-2 immunoreactivity in normal human tissues. J Histochem Cytochem. 1998;46:157–64.PubMed

18.

Yoshii M, Jikuhara A, Mori S, Iwagaki H, Takahashi HK, Nishibori M, Tanaka N. Mast cell tryptase stimulates DLD-1 carcinoma through prostaglandin- and MAP kinase-dependent manners. J Pharmacol Sci. 2005;98:450–8.PubMedCrossRef

19.

Fujimoto D, Hirono Y, Goi T, Katayama K, Hirose K, Yamaguchi A. Expression of protease activated receptor-2 (PAR-2) in gastric cancer. J Surg Oncol. 2006;93:139–44.PubMedCrossRef

20.

Ikeda O, Egami H, Ishiko T, Ishikawa S, Kamohara H, Hidaka H, et al. Expression of proteinase-activated receptor-2 in human pancreatic cancer: a possible relation to cancer invasion and induction of fibrosis. Int J Oncol. 2003;22:295–300.PubMed

21.

Shibata K, Yada K, Matsumoto T, Sasaki A, Ohta M, Kitano S. Protease-activating-receptor-2 is frequently expressed in papillary adenocarcinoma of the gallbladder. Oncol Rep. 2004;12:1013–6.PubMed

22.

Darmoul D, Marie JC, Devaud H, Gratio V, Laburthe M. Initiation of human colon cancer cell proliferation by trypsin acting at protease-activated receptor-2. Br J Cancer. 2001;85:772–9.PubMedCrossRef

23.

Ohta T, Shimizu K, Yi S, Takamura H, Amaya K, Kitagawa H, et al. Protease-activated receptor-2 expression and the role of trypsin in cell proliferation in human pancreatic cancers. Int J Oncol. 2003;23:61–6.PubMed

24.

Yada K, Shibata K, Matsumoto T, Ohta M, Yokoyama S, Kitano S. Protease-activated receptor-2 regulates cell proliferation and enhances cyclooxygenase-2 mRNA expression in human pancreatic cancer cells. J Surg Oncol. 2005;89:79–85.PubMedCrossRef

25.

Iwaki K, Shibata K, Ohta M, Endo Y, Uchida H, Tominaga M, et al. A small interfering RNA targeting proteinase-activated receptor-2 is effective in suppression of tumor growth in a Panc1 xenograft model. Int J Cancer. 2008;122:658–63.PubMedCrossRef

26.

Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part II). J Natl Cancer Inst. 1998;90:1609–20.PubMedCrossRef

27.

Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med. 1995;333:609–14.PubMedCrossRef

28.

Marnett LJ, DuBois RN. COX-2: a target for colon cancer prevention. Annu Rev Pharmacol Toxicol. 2002;42:55–80.PubMedCrossRef

29.

Sirica AE. Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology. 2005;41:5–15.PubMedCrossRef

30.

Wu T. Cyclooxygenase-2 and prostaglandin signaling in cholangiocarcinoma. Biochim Biophys Acta. 2005;1755:135–50.PubMed

31.

Kiguchi K, Carbajal S, Chan K, Beltran L, Ruffino L, Shen J, et al. Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. Cancer Res. 2001;61:6971–6.PubMed

32.

Endo K, Yoon BI, Pairojkul C, Demetris AJ, Sirica AE. ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology. 2002;36:439–50.PubMedCrossRef

33.

Han C, Leng J, Demetris AJ, Wu T. Cyclooxygenase-2 promotes human cholangiocarcinoma growth: evidence for cyclooxygenase-2-independent mechanism in celecoxib-mediated induction of p21waf1/cip1 and p27kip1 and cell cycle arrest. Cancer Res. 2004;64:1369–76.PubMedCrossRef

34.

Wu T, Leng J, Han C, Demetris AJ. The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells. Mol Cancer Ther. 2004;3:299–307.PubMed

35.

Syeda F, Grosjean J, Houliston RA, Keogh RJ, Carter TD, Paleolog E, et al. Cyclooxygenase-2 induction and prostacyclin release by protease-activated receptors in endothelial cells require cooperation between mitogen-activated protein kinase and NF-kappaB pathways. J Biol Chem. 2006;281:11792–804.PubMedCrossRef

36.

Kawao N, Nagataki M, Nagasawa K, Kubo S, Cushing K, Wada T, Sekiguchi F, Ichida S, Hollenberg MD, MacNaughton WK, Nishikawa H, Kawabata A. Signal transduction for proteinase-activated receptor-2-triggered prostaglandin E2 formation in human lung epithelial cells. J Pharmacol Exp Ther. 2005;315:576–89.PubMedCrossRef

37.

Nzeako UC, Guicciardi ME, Yoon JH, Bronk SF, Gores GJ. COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells. Hepatology. 2002;35:552–9.PubMedCrossRef

38.

Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 1995;83:493–501.PubMedCrossRef

39.

Darmoul D, Gratio V, Devaud H, Laburthe M. Protease-activated receptor 2 in colon cancer: trypsin-induced MAPK phosphorylation and cell proliferation are mediated by epidermal growth factor receptor transactivation. J Biol Chem. 2004;279:20927–34.PubMedCrossRef

40.

Wang H, Wen S, Bunnett NW, Leduc R, Hollenberg MD, MacNaughton WK. Proteinase-activated receptor-2 induces cyclooxygenase-2 expression through beta-catenin and cyclic AMP-response element-binding protein. J Biol Chem. 2008;283:809–15.PubMedCrossRef

41.

Jikuhara A, Yoshii M, Iwagaki H, Mori S, Nishibori M, Tanaka N. MAP kinase-mediated proliferation of DLD-1 carcinoma by the stimulation of protease-activated receptor 2. Life Sci. 2003;73:2817–29.PubMedCrossRef

42.

Yoon JH, Higuchi H, Werneburg NW, Kaufmann SH, Gores GJ. Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology. 2002;122:985–93.PubMedCrossRef

Title: Protease-activated receptor-2 regulates cyclooxygenase-2 expression in human bile duct cancer via the pathways of mitogen-activated protein kinases and nuclear factor kappa B
Authors: Hidetoshi Eguchi
Kentaro Iwaki
Kohei Shibata
Tadashi Ogawa
Masayuki Ohta
Seigo Kitano
Publication date: 01-03-2011
Publisher: Springer Japan
Published in: Journal of Hepato-Biliary-Pancreatic Sciences / Issue 2/2011
Print ISSN: 1868-6974
Electronic ISSN: 1868-6982
DOI: https://doi.org/10.1007/s00534-010-0318-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Protease-activated receptor-2 regulates cyclooxygenase-2 expression in human bile duct cancer via the pathways of mitogen-activated protein kinases and nuclear factor kappa B

Abstract

Background/purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background/purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2011

The distribution of atypical epithelium in main-duct type intraductal papillary mucinous neoplasms of the pancreas

Allopurinol and xanthine oxidase inhibition in liver ischemia reperfusion

Using the greater omental flap to cover the cut surface of the liver for prevention of delayed gastric emptying after left-sided hepatobiliary resection: a prospective randomized controlled trial

Accuracy of the Tokyo Guidelines for the diagnosis of acute cholangitis and cholecystitis taking into consideration the clinical practice pattern in Japan

Body surface area index predicts outcome in orthotopic liver transplantation

Donor quality of life after living donor liver transplantation: a prospective study